Travere Therapeutics posts corporate overview on rare kidney disease growth strategy, FILSPARI expansion and pipeline updates

FILSPARI momentum was highlighted by U.S. net sales of $141 million in 2Q26, supported by 2,012 new patient start forms, up 96%.

Pegtibatinase was positioned as a potential first disease-modifying therapy for classical HCU, with pivotal Phase 3 HARMONY topline data expected in 2H27.

Civorebrutinib was presented as a new growth platform with multi-indication potential in immune-mediated kidney diseases, including primary membranous nephropathy.

Travere Therapeutics outlined a growth plan centered on FILSPARI expansion in rare kidney disease, targeting a U.S. peak sales opportunity above $3 billion.

The company said the strategy assumes continued IgAN demand and accelerated adoption in FSGS following FDA clearance for patients aged 8 and older without nephrotic syndrome.